Heparin-induced thrombocytopenia
MONDO:0018048Heparin-induced thrombocytopenia (HIT) is a drug-induced, immune-mediated prothrombotic disorder associated with thrombocytopenia and venous and/or arterial thrombosis.
Also known as: HAT, HIT, heparin-associated thrombocytopenia, heparin-induced thrombocytopenia, heparin-induced thrombocytopenia (disease), heparin-induced thrombocytopenia type 2
9 clinical trials for this condition and its sub-types, 5 tagged with Heparin-induced thrombocytopenia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New blood thinner tested for rare clotting disorder
Disease control CompletedThis study looked at how well the drug argatroban works in 20 adults with a condition called heparin-induced thrombocytopenia Type II, where the blood thinner heparin causes low platelets and raises clot risk. Participants received argatroban to prevent new or worsening blood clo…
Phase 2 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New imaging method could speed up diagnosis of blood clotting disorders
Diagnosis CompletedThis study tested a new diagnostic tool that uses imaging flow cytometry to examine platelets in blood samples. Researchers compared it to standard lab tests in 31 patients suspected of having platelet disorders or heparin-induced thrombocytopenia. The goal was to see if the new …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
Scientists hunt for allergy genes in massive screening study
Knowledge-focused CompletedThis study screened up to 1,000 people with severe allergic conditions—like anaphylaxis, eczema, and asthma—along with their relatives to find genetic causes. Researchers collected blood samples and medical history to link specific gene mutations to these diseases. No treatment w…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC